

Lynley V Marshall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5524085/publications.pdf>

Version: 2024-02-01

44
papers

1,868
citations

471061

17
h-index

315357

38
g-index

45
all docs

45
docs citations

45
times ranked

3064
citing authors

#	ARTICLE	IF	CITATIONS
1	DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition. <i>Cancer Discovery</i> , 2022, 12, 712-729.	7.7	15
2	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. <i>European Journal of Cancer</i> , 2022, 160, 112-133.	1.3	24
3	Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours. <i>European Journal of Cancer</i> , 2022, 162, 209-220.	1.3	12
4	Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i> , <i>ROS1</i> , or <i>ALK</i> aberrations (STARTRK-NG). <i>Neuro-Oncology</i> , 2022, 24, 1776-1789.	0.6	37
5	ACCELERATE – Five years accelerating cancer drug development for children and adolescents. <i>European Journal of Cancer</i> , 2022, 166, 145-164.	1.3	28
6	Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10041-10041.	0.8	0
7	Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas. <i>European Journal of Cancer</i> , 2022, 173, 71-90.	1.3	9
8	Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients. <i>Neuro-Oncology Advances</i> , 2021, 3, v013.	0.4	27
9	High grade gliomas in young children: The South Thames Neuro-Oncology unit experience and recent advances in molecular biology and targeted therapies. <i>Pediatric Hematology and Oncology</i> , 2021, 38, 707-721.	0.3	6
10	Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 660892.	1.3	7
11	Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. <i>European Journal of Cancer</i> , 2021, 157, 198-213.	1.3	34
12	First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcS@-ESMART trial. <i>European Journal of Cancer</i> , 2021, 157, 268-277.	1.3	19
13	Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma. <i>European Journal of Cancer</i> , 2021, 158, 38-46.	1.3	9
14	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2020, 21, 121-133.	5.1	204
15	Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 2 study. <i>Lancet Oncology</i> , 2020, 21, 134-144.	5.1	103
16	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. <i>European Journal of Cancer</i> , 2020, 139, 135-148.	1.3	20
17	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. <i>European Journal of Cancer</i> , 2020, 141, 82-91.	1.3	15
18	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 52-66.	1.3	52

#	ARTICLE	IF	CITATIONS
19	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	7.7	157
20	Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK).. <i>Journal of Clinical Oncology</i> , 2020, 38, 10505-10505.	0.8	11
21	Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10507-10507.	0.8	6
22	How to address challenges and opportunities in pediatric cancer drug development?. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 869-872.	2.5	1
23	MODL-20. A BIOBANK OF ~100 PATIENT-DERIVED MODELS REPRESENTING BIOLOGICAL HETEROGENEITY AND DISTINCT THERAPEUTIC DEPENDENCIES IN PAEDIATRIC HIGH GRADE GLIOMA AND DIPG. <i>Neuro-Oncology</i> , 2020, 22, iii414-iii415.	0.6	2
24	High-dose etoposide and cyclophosphamide in adults and children with primary refractory and multiply relapsed acute leukaemias: The Royal Marsden experience. <i>Leukemia Research</i> , 2019, 85, 106217.	0.4	5
25	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. <i>European Journal of Cancer</i> , 2019, 121, 224-235.	1.3	44
26	Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas. <i>Pediatric Hematology and Oncology</i> , 2019, 36, 103-112.	0.3	7
27	ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. <i>European Journal of Cancer</i> , 2019, 110, 74-85.	1.3	39
28	A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10035-10035.	0.8	4
29	10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers. <i>Lancet Oncology</i> , The, 2018, 19, 285-287.	5.1	20
30	PDTM-34. TARGETING H3.3G34R/V RE-WIRING OF THE EPIGENOME IN PAEDIATRIC GLIOBLASTOMA OF CHILDREN AND YOUNG ADULTS. <i>Neuro-Oncology</i> , 2018, 20, vi211-vi211.	0.6	0
31	HGG-23. DRUG SCREENING LINKED TO MOLECULAR PROFILING IDENTIFIES NOVEL DEPENDENCIES IN PATIENT-DERIVED PRIMARY CULTURES OF PAEDIATRIC HIGH GRADE GLIOMA AND DIPG. <i>Neuro-Oncology</i> , 2018, 20, i93-i94.	0.6	1
32	PDTM-33. ATRX LOSS CONFERS ENHANCED SENSITIVITY TO COMBINED PARP INHIBITION AND RADIOTHERAPY IN PAEDIATRIC GLIOBLASTOMA MODELS. <i>Neuro-Oncology</i> , 2018, 20, vi210-vi211.	0.6	5
33	EAPH-05. MOLECULAR PROFILING AND IDENTIFICATION OF TARGETED THERAPIES FOR CHILDREN AND YOUNG ADULTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMOURS IN THE UNITED KINGDOM. <i>Neuro-Oncology</i> , 2018, 20, i66-i66.	0.6	0
34	PDTM-31. DRUG SCREENING LINKED TO MOLECULAR PROFILING IDENTIFIES NOVEL DEPENDENCIES IN PATIENT-DERIVED PRIMARY CULTURES OF PAEDIATRIC HIGH GRADE GLIOMA AND DIPG. <i>Neuro-Oncology</i> , 2018, 20, vi210-vi210.	0.6	0
35	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. <i>Nature Medicine</i> , 2018, 24, 1204-1215.	15.2	133
36	HGG-13. SURVIVAL OUTCOMES OF CHILDREN AND ADOLESCENTS WITH BI-THALAMIC GLIOMAS: THE SOUTH THAMES NEURO-ONCOLOGY UNIT EXPERIENCE. <i>Neuro-Oncology</i> , 2018, 20, i91-i91.	0.6	0

#	ARTICLE	IF	CITATIONS
37	KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1 ⁺ positive advanced, relapsed or refractory solid tumor or lymphoma.. Journal of Clinical Oncology, 2018, 36, 10525-10525.	0.8	10
38	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery, 2017, 12, 1-11.	2.5	28
39	Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium. European Journal of Cancer, 2017, 86, 275-284.	1.3	4
40	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell, 2017, 32, 520-537.e5.	7.7	716
41	Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1 ⁺ advanced, relapsed, or refractory solid tumor or lymphoma.. Journal of Clinical Oncology, 2017, 35, 10525-10525.	0.8	11
42	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. Oncotarget, 2017, 8, 112036-112050.	0.8	16
43	HG-99A PATIENT-DERIVED PAEDIATRIC HIGH GRADE GLIOMA AND DIPG CELL CULTURE PANEL RECAPITULATING THE GENOTYPIC AND PHENOTYPIC DIVERSITY OF THE DISEASE. Neuro-Oncology, 2016, 18, iii71.3-iii71.	0.6	0
44	Phase 1/2 study of pembrolizumab (pembro) in children with advanced melanoma or a PD-L1-positive (PD-L1 ⁺) advanced, relapsed, or refractory solid tumor or lymphoma (KEYNOTE-051).. Journal of Clinical Oncology, 2016, 34, TPS10585-TPS10585.	0.8	0